Theralink’s Proteomic Analysis Shows Promising Interim Results in Inova Schar Cancer Institute’s Molecular Tumor Board Implementation
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis for Precision Oncology Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today…